{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T02:15:15Z","timestamp":1778552115233,"version":"3.51.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00228-026-04063-1","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T01:23:28Z","timestamp":1777080208000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effects of renal impairment on the pharmacokinetics, safety, and tolerability of pudexacianinium (ASP5354) after IV administration: a mechanistic exploration"],"prefix":"10.1007","volume":"82","author":[{"given":"Tomoki","family":"Kojima","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayuko","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz","family":"Wojtkowski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sayuri","family":"Guro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Koibuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly S.","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Neutel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Almena L.","family":"Free","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisakuni","family":"Sekino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel P.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Takusagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"2","key":"4063_CR1","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nrurol.2012.254","volume":"10","author":"H Abboudi","year":"2013","unstructured":"Abboudi H, Ahmed K, Royle J, Khan MS, Dasgupta P, N\u2019Dow J (2013) Ureteric injury: a challenging condition to diagnose and manage. Nat Rev Urol 10(2):108\u2013115. https:\/\/doi.org\/10.1038\/nrurol.2012.254","journal-title":"Nat Rev Urol"},{"issue":"3","key":"4063_CR2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1177\/1756287214526767","volume":"6","author":"FN Burks","year":"2014","unstructured":"Burks FN, Santucci RA (2014) Management of iatrogenic ureteral injury. Ther Adv Urol 6(3):115\u2013124. https:\/\/doi.org\/10.1177\/1756287214526767","journal-title":"Ther Adv Urol"},{"issue":"6","key":"4063_CR3","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1097\/aog.0000000000001096","volume":"126","author":"B Teeluckdharry","year":"2015","unstructured":"Teeluckdharry B, Gilmour D, Flowerdew G (2015) Urinary tract injury at benign gynecologic surgery and the role of cystoscopy. Obstet Gynecol 126(6):1161\u20131169. https:\/\/doi.org\/10.1097\/aog.0000000000001096","journal-title":"Obstet Gynecol"},{"issue":"3","key":"4063_CR4","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/j.1464-410x.2004.04978.x","volume":"94","author":"S Brandes","year":"2004","unstructured":"Brandes S, Coburn M, Armenakas N, McAninch J (2004) Diagnosis and management of ureteric injury: an evidence-based analysis. BJU Int 94(3):277\u2013289. https:\/\/doi.org\/10.1111\/j.1464-410x.2004.04978.x","journal-title":"BJU Int"},{"issue":"6","key":"4063_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.21037\/qims.2019.06.15","volume":"9","author":"CB Ahn","year":"2019","unstructured":"Ahn CB, Kim JH, Park GK, Park KY, Bao K, Lee JW et al (2019) Prognostic imaging of iatrogenic and traumatic ureteral injury by near-infrared fluorescence. Quant Imaging Med Surg 9(6):1056\u20131065. https:\/\/doi.org\/10.21037\/qims.2019.06.15","journal-title":"Quant Imaging Med Surg"},{"issue":"4","key":"4063_CR6","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s10151-019-01973-4","volume":"23","author":"MD Slooter","year":"2019","unstructured":"Slooter MD, Janssen A, Bemelman WA, Tanis PJ, Hompes R (2019) Currently available and experimental dyes for intraoperative near-infrared fluorescence imaging of the ureters: a systematic review. Tech Coloproctology 23(4):305\u2013313. https:\/\/doi.org\/10.1007\/s10151-019-01973-4","journal-title":"Tech Coloproctology"},{"issue":"2","key":"4063_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.juro.2013.02.3187","volume":"190","author":"FPR Verbeek","year":"2013","unstructured":"Verbeek FPR, Van DVJR, Schaafsma BE, Swijnenburg R, Gaarenstroom KN, Elzevier HW et al (2013) Intraoperative near infrared fluorescence guided identification of the ureters using low dose methylene blue: A first in human experience. J Urol 190(2):574\u2013579. https:\/\/doi.org\/10.1016\/j.juro.2013.02.3187","journal-title":"J Urol"},{"issue":"2","key":"4063_CR8","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.eururo.2014.08.057","volume":"67","author":"Z Lee","year":"2015","unstructured":"Lee Z, Moore B, Giusto L, Eun DD (2015) Use of indocyanine green during robot-assisted ureteral reconstructions. Eur Urol 67(2):291\u2013298. https:\/\/doi.org\/10.1016\/j.eururo.2014.08.057","journal-title":"Eur Urol"},{"issue":"4","key":"4063_CR9","doi-asserted-by":"publisher","first-page":"436.e1","DOI":"10.1016\/j.ajog.2014.05.017","volume":"211","author":"S Siddighi","year":"2014","unstructured":"Siddighi S, Yune JJ, Hardesty J (2014) Indocyanine green for intraoperative localization of ureter. Am J Obstet Gynecol 211(4):436.e1-436.e2. https:\/\/doi.org\/10.1016\/j.ajog.2014.05.017","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"4063_CR10","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11307-021-01613-0","volume":"25","author":"H Fushiki","year":"2023","unstructured":"Fushiki H, Yoshikawa T, Matsuda T, Sato T, Suwa A (2023) Preclinical development and validation of ASP5354: A near-infrared fluorescent agent for intraoperative ureter visualization. Mol Imaging Biol 25(1):74\u201384. https:\/\/doi.org\/10.1007\/s11307-021-01613-0","journal-title":"Mol Imaging Biol"},{"issue":"12","key":"4063_CR11","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/cpdd.1013","volume":"10","author":"T Murase","year":"2021","unstructured":"Murase T, Takizawa M, Galitz L, Flach S, Murray V, Gufford B et al (2021) Randomized, double-blind, controlled study to evaluate safety and pharmacokinetics of single ascending doses of ASP5354, an investigational imaging product, in healthy adult volunteers. Clin Pharmacol Drug Dev 10(12):1460\u20131468. https:\/\/doi.org\/10.1002\/cpdd.1013","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"9","key":"4063_CR12","doi-asserted-by":"publisher","first-page":"7336","DOI":"10.1007\/s00464-023-10193-9","volume":"37","author":"M Albert","year":"2023","unstructured":"Albert M, Delgado-Herrera L, Paruch J, Gerritsen-van Schieveen P, Kishimoto T, Takusagawa S et al (2023) Pudexacianinium (ASP5354) chloride for ureter visualization in participants undergoing laparoscopic, minimally invasive colorectal surgery. Surg Endosc 37(9):7336\u20137347. https:\/\/doi.org\/10.1007\/s00464-023-10193-9","journal-title":"Surg Endosc"},{"issue":"1","key":"4063_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP (2022) Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 12(1):7\u201311. https:\/\/doi.org\/10.1016\/j.kisu.2021.11.003","journal-title":"Kidney Int Suppl"},{"issue":"7","key":"4063_CR14","doi-asserted-by":"publisher","first-page":"e01587","DOI":"10.1371\/journal.pone.0158765","volume":"11","author":"NR Hill","year":"2016","unstructured":"Hill NR, Fatoba ST, Oke JL, Hirst JA, O\u2019Callaghan CA, Lasserson DS et al (2016) Global prevalence of chronic kidney disease - A systematic review and meta-analysis. PLoS ONE 11(7):e01587. https:\/\/doi.org\/10.1371\/journal.pone.0158765","journal-title":"PLoS ONE"},{"issue":"10","key":"4063_CR15","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/diagnostics13101823","volume":"13","author":"K Teranishi","year":"2023","unstructured":"Teranishi K (2023) Evaluation of the utilization of near-infrared fluorescent contrast agent ASP5354 for in vivo ureteral identification in renal diseases using rat models of gentamicin-induced acute kidney injury. Diagnostics 13(10):1823. https:\/\/doi.org\/10.3390\/diagnostics13101823","journal-title":"Diagnostics"},{"issue":"4","key":"4063_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen S et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145(4):247\u2013254. https:\/\/doi.org\/10.7326\/0003-4819-145-4-200608150-00004","journal-title":"Ann Intern Med"},{"key":"4063_CR17","unstructured":"Du Bois D, Du Bois EF (1989) A formula to estimate the approximate surface area if height and weight be known. 1916. Nutrition 5:303\u2013311. Discussion 312\u2013303"},{"key":"4063_CR18","unstructured":"FDA Guidance for Industry (2020) Pharmacokinetics in patients with impaired renal function: Study design, data analysis, and impact on dosing and labeling. https:\/\/www.fda.gov\/media\/78573\/download. Accessed 22 Jan 2025"},{"issue":"6","key":"4063_CR19","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1046\/j.1523-1755.2000.00431.x","volume":"58","author":"KA P\u00f6schel","year":"2000","unstructured":"P\u00f6schel KA, Bucha E, Esslinger HU, N\u00f6rtersheuser P, Jansa U, Schindler U, Nowak G et al (2000) Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Kidney Int 58(6):2478\u20132484. https:\/\/doi.org\/10.1046\/j.1523-1755.2000.00431.x","journal-title":"Kidney Int"},{"issue":"5","key":"4063_CR20","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1002\/cpdd.750","volume":"9","author":"AN Nafziger","year":"2020","unstructured":"Nafziger AN, Arscott KA, Cochrane K, Skobieranda F, Burt DA, Fossler MJ (2020) The influence of renal or hepatic impairment on the pharmacokinetics, safety, and tolerability of oliceridine. Clin Pharmacol Drug Dev 9(5):639\u2013650. https:\/\/doi.org\/10.1002\/cpdd.750","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"S1","key":"4063_CR21","doi-asserted-by":"publisher","first-page":"79S","DOI":"10.1177\/0091270011415410","volume":"52","author":"L Zhang","year":"2012","unstructured":"Zhang L, Xu N, Xiao S, Arya V, Zhao P, Lesko LJ et al (2012) Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease. J Clin Pharmacol 52(S1):79S-90S. https:\/\/doi.org\/10.1177\/0091270011415410","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"4063_CR22","doi-asserted-by":"publisher","first-page":"799","DOI":"10.2165\/11537850-000000000-00000","volume":"49","author":"HM Faessel","year":"2010","unstructured":"Faessel HM, Obach RS, Rollema H, Ravva P, Williams KE, Burstein (2010) A review of the clinical pharmacokinetics and pharmacodynamics of varenicline for smoking cessation. Clin Pharmacokinet. 49(12):799\u2013816. https:\/\/doi.org\/10.2165\/11537850-000000000-00000","journal-title":"Clin Pharmacokinet."},{"issue":"12","key":"4063_CR23","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1002\/jps.21370","volume":"97","author":"T Nakatani-Freshwater","year":"2008","unstructured":"Nakatani-Freshwater T, Taft DR (2008) Renal excretion of emtricitabine I: Effects of organic anion, organic cation, and nucleoside transport inhibitors on emtricitabine excretion. J Pharm Sci 97(12):5401\u20135410. https:\/\/doi.org\/10.1002\/jps.21370","journal-title":"J Pharm Sci"},{"issue":"12","key":"4063_CR24","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1128\/aac.34.12.2364","volume":"34","author":"RA Blum","year":"1990","unstructured":"Blum RA, Schultz RW, Schentag JJ (1990) Pharmacokinetics of lomefloxacin in renally compromised patients. Antimicrob Agents Chemother 34(12):2364\u20132368. https:\/\/doi.org\/10.1128\/aac.34.12.2364","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"4063_CR25","doi-asserted-by":"publisher","first-page":"6260","DOI":"10.1128\/aac.00986-16","volume":"60","author":"X Yang","year":"2016","unstructured":"Yang X, Ma Z, Zhou S, Weng Y, Lei H, Zeng S et al (2016) Multiple drug transporters are involved in renal secretion of entecavir. Antimicrob Agents Chemother 60(10):6260\u20136270. https:\/\/doi.org\/10.1128\/aac.00986-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"4063_CR26","doi-asserted-by":"publisher","first-page":"4231","DOI":"10.1128\/aac.00557-07","volume":"51","author":"XJ Zhou","year":"2007","unstructured":"Zhou XJ, Swan S, Smith WB, Marbury TC, Dubuc-Patrick G, Chao GC et al (2007) Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 51(12):4231\u20134235. https:\/\/doi.org\/10.1128\/aac.00557-07","journal-title":"Antimicrob Agents Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04063-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04063-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:46:02Z","timestamp":1778550362000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04063-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["4063"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04063-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"18 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical study was conducted in accordance with the principles of the Declaration of Helsinki, Good Clinical Practice, and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. The protocol, its amendments, informed consent forms, investigator\u2019s brochure, and other relevant documents (e.g., advertisements) were reviewed and approved by the Institutional Review Board of the participating sites (Advarra, Inc., Columbia, MD, for sites in the USA; and Medical Corporation Houeikai, Toshima-ku, Tokyo, for the site in Japan) before the study was initiated. All participants provided written informed consent before participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"TK, MS, TM, MN, SG, AK, MM, and ST are employees of Astellas Pharma Inc. NS is an employee of Astellas Research Institute of America, LLC. TW and GPH are employees of Astellas Pharma Global Development, Inc. KSC, JMN, ALF, and HS have no conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"131"}}